IREIT Global Valuation
Is UD1U undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
3/6Valuation Score 3/6
Unter dem Marktwert
Deutlich unter dem Marktwert
Price-To-Sales gegen Gleichaltrige
Price-To-Sales gegen Industrie
PM vs. Fair Ratio
Analysten-Prognose
Share Price vs Fair Value
What is the Fair Price of UD1U when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Unter dem Marktwert: UD1U (SGD0.39) wird unter unserer Schätzung des Fair Value (SGD0.55) gehandelt.
Deutlich unter dem Marktwert: UD1U wird um mehr als 20 % unter dem Marktwert gehandelt.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for UD1U?
Other financial metrics that can be useful for relative valuation.
| What is UD1U's n/a Ratio? | |
|---|---|
| n/a | 0x |
| n/a | n/a |
| Market Cap | €322.36m |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 10.1x |
| Enterprise Value/EBITDA | n/a |
| PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does UD1U's PS Ratio compare to its peers?
| Company | Forward PS | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 1.5x | ||
MXNU Elite Commercial REIT | 3.2x | -5.4% | UK£146.8m |
OXMU Prime US REIT | 1x | 2.7% | US$167.5m |
CMOU Keppel Pacific Oak US REIT | 1.1x | -0.4% | US$158.8m |
BTOU Manulife US Real Estate Investment Trust | 0.6x | -5.2% | US$131.5m |
UD1U IREIT Global | 5x | 0.5% | S$470.7m |
Price-To-Sales gegen Gleichaltrige: UD1U ist auf der Grundlage des Price-To-Sales Verhältnisses (6x) im Vergleich zum Durchschnitt der Vergleichsgruppe (1.8x) teuer.
Price to Earnings Ratio vs Industry
How does UD1U's PE Ratio compare vs other companies in the Asian Office REITs Industry?
Price-To-Sales gegen Industrie: UD1U ist aufgrund seines Price-To-Sales Verhältnisses (6x) im Vergleich zum Asian Office REITs Branchendurchschnitt (7x) ein guter Wert.
Price to Sales Ratio vs Fair Ratio
What is UD1U's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PS Ratio | 5x |
| Fair PS Ratio | 4.8x |
PM vs. Fair Ratio: UD1U ist teuer auf der Grundlage des Verhältnisses Price-To-Sales (5x) im Vergleich zum geschätzten fairen Verhältnis Price-To-Sales (4.8x).
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
| Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
|---|---|---|---|---|---|---|---|
| Current | S$0.35 | S$0.46 +30.3% | 3.0% | S$0.47 | S$0.44 | n/a | 2 |
| Mar ’25 | S$0.35 | S$0.46 +30.3% | 3.0% | S$0.47 | S$0.44 | n/a | 2 |
| Feb ’25 | S$0.40 | S$0.46 +14.0% | 2.9% | S$0.47 | S$0.44 | n/a | 2 |
| Jan ’25 | S$0.41 | S$0.43 +6.7% | 3.0% | S$0.45 | S$0.42 | n/a | 2 |
| Dec ’24 | S$0.36 | S$0.43 +18.4% | 3.0% | S$0.45 | S$0.42 | n/a | 2 |
| Nov ’24 | S$0.34 | S$0.43 +29.0% | 3.0% | S$0.45 | S$0.42 | n/a | 2 |
| Oct ’24 | S$0.40 | S$0.43 +9.4% | 3.0% | S$0.45 | S$0.42 | n/a | 2 |
| Sep ’24 | S$0.40 | S$0.50 +25.5% | 9.2% | S$0.54 | S$0.45 | n/a | 2 |
| Aug ’24 | S$0.43 | S$0.57 +31.1% | 7.0% | S$0.61 | S$0.53 | n/a | 2 |
| Jul ’24 | S$0.44 | S$0.57 +29.6% | 7.0% | S$0.61 | S$0.53 | n/a | 2 |
| Jun ’24 | S$0.48 | S$0.59 +21.0% | 6.0% | S$0.62 | S$0.55 | n/a | 2 |
| May ’24 | S$0.50 | S$0.59 +17.3% | 6.0% | S$0.62 | S$0.55 | n/a | 2 |
| Apr ’24 | S$0.49 | S$0.58 +16.4% | 4.6% | S$0.60 | S$0.55 | S$0.35 | 2 |
| Mar ’24 | S$0.52 | S$0.58 +10.8% | 4.6% | S$0.60 | S$0.55 | S$0.35 | 2 |
| Feb ’24 | S$0.56 | S$0.62 +10.4% | 2.1% | S$0.63 | S$0.61 | S$0.40 | 2 |
| Jan ’24 | S$0.51 | S$0.62 +22.5% | 2.1% | S$0.63 | S$0.61 | S$0.41 | 2 |
| Dec ’23 | S$0.53 | S$0.62 +16.7% | 2.1% | S$0.63 | S$0.61 | S$0.36 | 2 |
| Nov ’23 | S$0.51 | S$0.70 +38.3% | 2.7% | S$0.72 | S$0.68 | S$0.34 | 2 |
| Oct ’23 | S$0.50 | S$0.70 +39.6% | 2.7% | S$0.72 | S$0.68 | S$0.40 | 2 |
| Sep ’23 | S$0.56 | S$0.70 +23.6% | 2.7% | S$0.72 | S$0.68 | S$0.40 | 2 |
| Aug ’23 | S$0.59 | S$0.71 +19.3% | 4.2% | S$0.74 | S$0.68 | S$0.43 | 2 |
| Jul ’23 | S$0.61 | S$0.71 +16.3% | 4.2% | S$0.74 | S$0.68 | S$0.44 | 2 |
| Jun ’23 | S$0.61 | S$0.71 +15.4% | 4.2% | S$0.74 | S$0.68 | S$0.48 | 2 |
| May ’23 | S$0.64 | S$0.72 +12.4% | 2.9% | S$0.74 | S$0.70 | S$0.50 | 2 |
| Apr ’23 | S$0.64 | S$0.72 +12.4% | 2.9% | S$0.74 | S$0.70 | S$0.49 | 2 |
Analysten-Prognose: Das Kursziel liegt mehr als 20% über dem aktuellen Aktienkurs, aber es gibt nicht genügend Analysten, die die Aktie beobachten, um eine statistische Sicherheit für eine Übereinstimmung zu ermitteln.